Design, synthesis, and: In vitro and in vivo characterization of 1-{4-[4-(substituted)piperazin-1-yl]butyl}guanidines and their piperidine analogues as histamine H 3 receptor antagonists

Marek Staszewski, Anna Stasiak, Tadeusz Karcz, Daniel McNaught Flores, Wiesława Agnieszka Fogel, Katarzyna Kieć-Kononowicz, Rob Leurs, Krzysztof Walczyński

Research output: Contribution to JournalArticleAcademicpeer-review

Abstract

Previously, we have shown that 1-substituted-[4-(7-phenoxyheptylpiperazin-1-yl)butyl]guanidine with electron withdrawing substituents at position 4 in the benzyl moiety exhibits high in vitro affinities toward the guinea pig jejunal histamine H 3 receptor with pA 2 ranging from 8.49 to 8.43. Here, we present data on the impact of replacement of the piperazine scaffold by the piperidine ring (compounds 2a and 2b), moving benzyl- and 4-trifluoromethylbenzyl substituents from position 1 to 3 of the guanidine moiety (compounds 2c and 2d), which decreases the guanidine basicity (compound 2e), and the influence of individual synthons (compounds 2f-h), present in the lead compounds 1b and 1c, on the antagonistic activity against the histamine H 3 receptor. Additionally, the most active compounds 1a, 1c, and 1d were evaluated for their affinity to the rat histamine H 3 receptor and the human histamine H 3 and H 4 receptors. It was also shown that compounds 1a, 1c and 1d, given parenterally for five days, reduced the food intake of rats and did not influence the brain histamine or noradrenaline concentrations; however, significantly reduced serotonin and dopamine concentrations were found in rats administered with compounds 1a and 1c, respectively.

LanguageEnglish
Pages234-251
Number of pages18
JournalMedChemComm
Volume10
Issue number2
DOIs
Publication statusPublished - Feb 2019

Fingerprint

Guanidines
Histamine
Guanidine
Rats
Histamine Receptors
Lead compounds
Dopamine
Serotonin
Norepinephrine
Alkalinity
Guinea Pigs
Scaffolds
Eating
Electrons
Brain
piperidine
In Vitro Techniques

Cite this

Staszewski, Marek ; Stasiak, Anna ; Karcz, Tadeusz ; McNaught Flores, Daniel ; Fogel, Wiesława Agnieszka ; Kieć-Kononowicz, Katarzyna ; Leurs, Rob ; Walczyński, Krzysztof. / Design, synthesis, and: In vitro and in vivo characterization of 1-{4-[4-(substituted)piperazin-1-yl]butyl}guanidines and their piperidine analogues as histamine H 3 receptor antagonists. In: MedChemComm. 2019 ; Vol. 10, No. 2. pp. 234-251.
@article{827a832160f34697ab1371c8e291edf9,
title = "Design, synthesis, and: In vitro and in vivo characterization of 1-{4-[4-(substituted)piperazin-1-yl]butyl}guanidines and their piperidine analogues as histamine H 3 receptor antagonists",
abstract = "Previously, we have shown that 1-substituted-[4-(7-phenoxyheptylpiperazin-1-yl)butyl]guanidine with electron withdrawing substituents at position 4 in the benzyl moiety exhibits high in vitro affinities toward the guinea pig jejunal histamine H 3 receptor with pA 2 ranging from 8.49 to 8.43. Here, we present data on the impact of replacement of the piperazine scaffold by the piperidine ring (compounds 2a and 2b), moving benzyl- and 4-trifluoromethylbenzyl substituents from position 1 to 3 of the guanidine moiety (compounds 2c and 2d), which decreases the guanidine basicity (compound 2e), and the influence of individual synthons (compounds 2f-h), present in the lead compounds 1b and 1c, on the antagonistic activity against the histamine H 3 receptor. Additionally, the most active compounds 1a, 1c, and 1d were evaluated for their affinity to the rat histamine H 3 receptor and the human histamine H 3 and H 4 receptors. It was also shown that compounds 1a, 1c and 1d, given parenterally for five days, reduced the food intake of rats and did not influence the brain histamine or noradrenaline concentrations; however, significantly reduced serotonin and dopamine concentrations were found in rats administered with compounds 1a and 1c, respectively.",
author = "Marek Staszewski and Anna Stasiak and Tadeusz Karcz and {McNaught Flores}, Daniel and Fogel, {Wiesława Agnieszka} and Katarzyna Kieć-Kononowicz and Rob Leurs and Krzysztof Walczyński",
year = "2019",
month = "2",
doi = "10.1039/c8md00527c",
language = "English",
volume = "10",
pages = "234--251",
journal = "MedChemComm",
issn = "2040-2503",
publisher = "Royal Society of Chemistry",
number = "2",

}

Design, synthesis, and: In vitro and in vivo characterization of 1-{4-[4-(substituted)piperazin-1-yl]butyl}guanidines and their piperidine analogues as histamine H 3 receptor antagonists. / Staszewski, Marek; Stasiak, Anna; Karcz, Tadeusz; McNaught Flores, Daniel; Fogel, Wiesława Agnieszka; Kieć-Kononowicz, Katarzyna; Leurs, Rob; Walczyński, Krzysztof.

In: MedChemComm, Vol. 10, No. 2, 02.2019, p. 234-251.

Research output: Contribution to JournalArticleAcademicpeer-review

TY - JOUR

T1 - Design, synthesis, and: In vitro and in vivo characterization of 1-{4-[4-(substituted)piperazin-1-yl]butyl}guanidines and their piperidine analogues as histamine H 3 receptor antagonists

AU - Staszewski, Marek

AU - Stasiak, Anna

AU - Karcz, Tadeusz

AU - McNaught Flores, Daniel

AU - Fogel, Wiesława Agnieszka

AU - Kieć-Kononowicz, Katarzyna

AU - Leurs, Rob

AU - Walczyński, Krzysztof

PY - 2019/2

Y1 - 2019/2

N2 - Previously, we have shown that 1-substituted-[4-(7-phenoxyheptylpiperazin-1-yl)butyl]guanidine with electron withdrawing substituents at position 4 in the benzyl moiety exhibits high in vitro affinities toward the guinea pig jejunal histamine H 3 receptor with pA 2 ranging from 8.49 to 8.43. Here, we present data on the impact of replacement of the piperazine scaffold by the piperidine ring (compounds 2a and 2b), moving benzyl- and 4-trifluoromethylbenzyl substituents from position 1 to 3 of the guanidine moiety (compounds 2c and 2d), which decreases the guanidine basicity (compound 2e), and the influence of individual synthons (compounds 2f-h), present in the lead compounds 1b and 1c, on the antagonistic activity against the histamine H 3 receptor. Additionally, the most active compounds 1a, 1c, and 1d were evaluated for their affinity to the rat histamine H 3 receptor and the human histamine H 3 and H 4 receptors. It was also shown that compounds 1a, 1c and 1d, given parenterally for five days, reduced the food intake of rats and did not influence the brain histamine or noradrenaline concentrations; however, significantly reduced serotonin and dopamine concentrations were found in rats administered with compounds 1a and 1c, respectively.

AB - Previously, we have shown that 1-substituted-[4-(7-phenoxyheptylpiperazin-1-yl)butyl]guanidine with electron withdrawing substituents at position 4 in the benzyl moiety exhibits high in vitro affinities toward the guinea pig jejunal histamine H 3 receptor with pA 2 ranging from 8.49 to 8.43. Here, we present data on the impact of replacement of the piperazine scaffold by the piperidine ring (compounds 2a and 2b), moving benzyl- and 4-trifluoromethylbenzyl substituents from position 1 to 3 of the guanidine moiety (compounds 2c and 2d), which decreases the guanidine basicity (compound 2e), and the influence of individual synthons (compounds 2f-h), present in the lead compounds 1b and 1c, on the antagonistic activity against the histamine H 3 receptor. Additionally, the most active compounds 1a, 1c, and 1d were evaluated for their affinity to the rat histamine H 3 receptor and the human histamine H 3 and H 4 receptors. It was also shown that compounds 1a, 1c and 1d, given parenterally for five days, reduced the food intake of rats and did not influence the brain histamine or noradrenaline concentrations; however, significantly reduced serotonin and dopamine concentrations were found in rats administered with compounds 1a and 1c, respectively.

UR - http://www.scopus.com/inward/record.url?scp=85062064146&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062064146&partnerID=8YFLogxK

U2 - 10.1039/c8md00527c

DO - 10.1039/c8md00527c

M3 - Article

VL - 10

SP - 234

EP - 251

JO - MedChemComm

T2 - MedChemComm

JF - MedChemComm

SN - 2040-2503

IS - 2

ER -